SuspendedPhase 2

Study of the Oral Treatment MTR-601 in Cervical Dystonia

Stopped: Pending further safety evaluation

United States80 participantsStarted 2025-02-28

Plain-language summary

Study MTR-601-201 is an 8-week, randomized, placebo-controlled study to examine the safety, tolerability, and efficacy of MTR-601 in participants with cervical dystonia.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Willing to adhere to study procedures and provide written informed consent prior to the start of any study procedures.
✓. Confirmed clinical diagnosis of cervical dystonia with the following:
✓. Adults 18-80 years of age at the time of consent.
✓. Weight ≥40 kg and body mass index (BMI) ≤35 kg/m2.
✓. Agree to practice highly effective birth control starting at screening and continuing for 30 days (females) or 90 days (males) after study treatment ends.
✓. History of, or physical examination findings indicating, clinically significant endocrine, neurological, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or muscle abnormalities or diseases that, in the opinion of the Investigator, renders the participant unsuitable for the study.
✓. History of any of the following:
✓. Use of the following treatment for cervical dystonia:

What they're measuring

To evaluate the safety and tolerability of MTR-601 by the incidents of treatment-related adverse events as assessed by CTCAE v5.0

Timeframe: Baseline to week 6

To evaluate the efficacy of MTR-601 in participants with cervical dystonia

Timeframe: Baseline to week 4

Trial details

NCT IDNCT06830642

SponsorMotric Bio

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-07-08

View on ClinicalTrials.gov More Cervical Dystonia trials